A Phase 2 Study of GW572016 in Hormone Naive Recurrent or Metastatic Hormone Sensitive Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 07 May 2013
At a glance
- Drugs Lapatinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 11 Jul 2012 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 18 Nov 2007 Status changed from in progress to completed.